跨性别者性别肯定手术标本中癌症及癌前病变的发生率
该研究回顾性分析了2017至2018年间在同一机构由单一位整形外科医生和单一位泌尿重建外科医生实施的295例跨性别性别肯定手术,其中6.4%的患者在常规病理评估中发现非典型病变。作者主张所有手术标本均应送病理评估。
要点
- 性别肯定手术常规废弃组织病理评估中非典型病变发生率为6.4%。
- 研究纳入双侧乳房切除术、阴道成形术加睾丸切除术及阴茎成形术中的阴道切除术标本。
- 建议所有性别肯定手术标本均送病理评估以发现潜在癌前或恶性病变。
核心结论
- 性别肯定手术常规病理标本中发现需进一步评估的非典型病变率为6.4%。
研究设计与样本
- 回顾性综述,纳入2017至2018年间在同一机构由单一位整形外科医生和单一位泌尿重建外科医生实施的295例跨性别性别肯定手术患者。
主要发现
- 共实施193例双侧乳房切除术、94例阴道成形术加睾丸切除术和8例阴道切除术。
- 6.4%的患者在常规病理评估中发现非典型病变。
临床怎么用
- 作者主张所有性别肯定手术产生的标本均应送病理评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gender-affirming surgery is becoming increasingly more common. Procedures including chest masculinization, breast augmentation, vaginoplasty, metoidioplasty, and phalloplasty routinely generate discarded tissue. The incidence of finding an occult malignancy or premalignant lesion in specimens from gender-affirming surgery is unknown. The authors therefore conducted a retrospective review of all transgender patients at their institution who underwent gender-affirming surgery to determine the incidence of precancerous and malignant lesions found incidentally. METHODS: A retrospective review of transgender patients who underwent gender-affirming surgery at the authors' institution between 2017 and 2018 performed by a single plastic surgeon and a single reconstructive urologic surgeon was conducted. Only transgender patients who underwent gender-affirming surgery that led to routine pathologic review of discarded tissue (mastectomy, vaginoplasty, vaginectomy as part of phalloplasty) were included. Charts were reviewed and patient demographics, duration of hormonal therapy, medical comorbidities, genetic risk factors for cancer, medications (including steroids or other immunosuppressants), pathology reports, and cancer management were recorded. RESULTS: Between 2017 and 2018, 295 transgender patients underwent gender-affirming surgery that generated discarded tissue sent for pathologic evaluation. During this period, 193 bilateral mastectomies, 94 vaginoplasties with orchiectomies, and eight vaginectomies were performed; 6.4 percent of all patients had an atypical lesion found on routine pathologic evaluation. CONCLUSIONS: Gender-affirming surgery is increasingly more common given the increase in access to care. The authors' review of routine pathologic specimens generated from gender-affirming surgery yielded a 6.4 percent rate of finding atypical lesions requiring further evaluation. The authors advocate that all specimens be sent for pathologic evaluation.
引用
- Jacoby A, Rifkin W, Zhao LC, et al. Incidence of Cancer and Premalignant Lesions in Surgical Specimens of Transgender Patients. Plast Reconstr Surg. 2021. PMID: 33370065. doi:10.1097/PRS.0000000000007452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。